Abalam Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Abalam Tablet is a fixed-dose combination of two nucleoside/nucleotide reverse transcriptase inhibitors, abacavir and lamivudine. It is prescribed as part of antiretroviral therapy for HIV infection, interfering with the enzymes the virus needs to reproduce and helping to reduce the risk of progression to AIDS.

Active ingredients
Abacavir + Lamivudine
Dosage form
Oral tablet
Therapeutic class
NRTI combination (antiretroviral)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with abacavir and lamivudine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Treatment of HIV-1 infection, as part of combination antiretroviral therapy
  • Described as reducing the likelihood of progression to AIDS when taken as prescribed
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Taken orally at the dose and duration prescribed; the course should not be interrupted
  • Stored in a cool, dry place away from direct sunlight, per manufacturer guidance
  • The prescribed dose should not be exceeded

Described Side Effects

Commonly described side effects include:

  • Headache
  • Tiredness and dizziness
  • Nausea and diarrhoea
  • Rash
  • Fever

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Serious hypersensitivity reactions have been associated with abacavir; treatment requires medical supervision and prompt review of any new symptoms
  • Not indicated for patients under 18 years of age, per manufacturer guidance
  • Alcohol should be avoided, as it may increase the risk of liver damage
  • Caution with driving or tasks needing concentration; pregnancy, planned pregnancy, or breastfeeding should be discussed with the prescriber

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, Abalam Tablet combines abacavir and lamivudine and is used within combination antiretroviral therapy for HIV-1 infection. SDO Pharma has not independently verified these claims.

Yes. Abacavir-containing therapy requires ongoing medical supervision, including assessment for hypersensitivity reactions and monitoring during treatment.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services